In addition anti-CTLA-4 monotherapy, trials are ongoing with anti-CTLA-4 (ipilimumab) combined with ProstVac-VF [82] or a GM-CSF-secreting whole tumor cell vaccine (GVAX; BioSante Pharmaceuticals) in prostate cancer [83]. This evidence concerns the gene CSF2 and neoplasm.